Inventiva S.A. (EPA:IVA)

Market Cap	710.36M +76.7%
Revenue (ttm)	6.76M -52.0%
Net Income	-354.14M
EPS	-1.90
Shares Out	207.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	316,356
Open	3.340
Previous Close	3.310
Day's Range	3.280 - 3.430
52-Week Range	2.560 - 6.200
Beta	0.88
Analysts	Strong Buy
Price Target	9.63 (+181.58%)
Earnings Date	Sep 25, 2026

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 77
• Stock Exchange: Euronext Paris
• Ticker Symbol: IVA

Financial Performance

In 2025, Inventiva's revenue was 6.76 million, a decrease of -52.03% compared to the previous year's 14.10 million. Losses were -354.14 million, 92.2% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for IVA stock is "Strong Buy." The 12-month stock price target is €9.63, which is an increase of 181.58% from the latest price.

Price Target

€9.63

(181.58% upside)

Analyst Consensus: Strong Buy